Kyverna Therapeutics

We’re very pleased to share positive primary analysis results from our registrational trial in #StiffPersonSyndrome: https://lnkd.in/en4JDEtE The findings, featured as a late-breaking oral presentation at the American Academy of Neurology’s #AANAM, underscore the potential for our investigational CAR T-cell therapy, miv-cel, to become the first and only approved treatment for SPS, fundamentally changing the treatment paradigm for this rare, progressive disease. We will host an IR call on April 22 at 7 am ET to review these results. Access details in the link above. #AAN2026 #CARTCellTherapy #Neuroimmunology #AutoimmuneDisease #RareDisease #ChronicDisease #Biotech

We’re pleased to share positive longer-term follow-up Phase 2 data for our investigational CAR T-cell therapy, miv-cel, in generalized #MyastheniaGravis: https://lnkd.in/ezF2DUKW The data, featured as an oral presentation at the American Academy of Neurology's #AANAM, reinforce miv-cel’s potential to set a new clinical standard in gMG. For people navigating #MG, progress matters. We’re grateful to the trial participants and clinical investigators who make it possible. We will host an IR call on April 22 at 7 am ET to review these results. Access details available in the link above. #AAN2026 #CARTCellTherapy #Neuroimmunology #AutoimmuneDisease #RareDisease #ChronicDisease #Biotech

We’re excited to connect at the American Academy of Neurology's #AANAM and discuss several data updates from our neuroimmunology CAR T franchise: https://lnkd.in/ePnPehJn Every conversation is a step forward in our effort to advance CAR T-cell therapies and change the treatment paradigm for people living with neurologic autoimmune diseases. We look forward to sharing key data updates from our late-stage clinical programs in #StiffPersonSyndrome and generalized #MyastheniaGravis, as well as meeting with clinicians and researchers to exchange ideas and help shape what’s next. #AAN2026 #CARTCellTherapy #RareDisease #Neuroimmunology #AutoimmuneDisease #Biotech

Congratulations to the Myasthenia Gravis Foundation of America, Inc. on another successful National Patient Conference! We are grateful for the opportunity to engage with the community of #MyastheniaGravis caregivers and patients like Kathy Timothy who shared why this event is so valuable. To learn more about our KYSA-6 CAR T clinical trial in gMG, visit: myastheniagravistrials.com #CARTcelltherapy #RareDisease #MG #neuroimmunology #AutoimmuneDisease #MGstrong #ClinicalTrial

On Wednesday, April 22, at 7:00 AM ET, we will host a conference call to discuss the primary analysis results from the KYSA‑8 registrational trial of our investigational CAR T-cell therapy, miv‑cel (KYV-101), in #StiffPersonSyndrome, along with longer‑term follow‑up data from the KYSA‑6 Phase 2 trial in generalized #myastheniagravis. These data will be shared as oral presentations at the American Academy of Neurology meeting, #AANAM, April 18-22, 2026, in Chicago. See the full release for more details on how to register and join the call: https://lnkd.in/eK6j5zUd #CARTcelltherapy #raredisease #neuroimmunology #autoimmunedisease #biotech #AAN2026

Today, we shared our Q4 and Full Year 2025 financial results, highlighting our continued leadership in building a first-in-class neuroimmunology CAR T franchise.     Last quarter, we reported landmark topline data of our investigational therapy, miv-cel, in stiff person syndrome (SPS), a serious and debilitating disease with no FDA approved treatments. In addition, we shared positive interim data from the Phase 2 portion of the KYSA-6 clinical trial in generalized myasthenia gravis (gMG) as well as promising data in progressive multiple sclerosis, underscoring the valuable pipeline-in-a-product opportunity we have with miv-cel.    We will present additional data in gMG and SPS at the 2026 American Academy of Neurology (AAN) meeting in April, as we actively prepare for our SPS BLA filing and potential commercial launch.    For more details, read the full release: https://bit.ly/4uVoa1d

We were pleased to recently participate in the San Francisco Myasthenia Gravis Foundation of America, Inc. Community Health Fair and share information about our Phase 3 CAR T-cell therapy clinical trial in generalized myasthenia gravis (gMG), called KYSA-6. Thank you, MGFA, for hosting these events that facilitate community-level education and empower patients living with #myastheniagravis. You can learn more about our KYSA-6 trial by visiting myastheniagravistrials.com. #MG #CARTcelltherapy #autoimmune #neuroimmunology

This Sunday, on #InternationalSPSAwarenessDay, it’s important we come together and shine a light on this rare and progressive autoimmune disease.     At Kyverna, our goal is to provide meaningful clinical outcomes in SPS and other neurological diseases. Together, we can raise awareness, drive innovation forward, and bring hope to those in need.    #neuroimmunology #autoimmunediseases #stiffpersonsyndrome #CARTcelltherapy #raredisease

We look forward to sharing important new data from our neuroimmunology franchise at the American Academy of Neurology (AAN) 2026 Annual Meeting, which will take place from April 18-22, 2026, in Chicago.     This includes two oral presentations from our late-stage clinical programs–the primary analysis from our KYSA-8 registrational trial in stiff person syndrome and updated KYSA-6 Phase 2 data in generalized myasthenia gravis. We hope to see you there!       Read more: https://bit.ly/4lfjKxU   #AAN2026 #AANAM #Neuroimmunology #SPS #MG 

Join our team at upcoming investor conferences in Miami, where we will share our latest company highlights and near-term catalysts. Learn more here: https://bit.ly/4u1hqyB  A live webcast of our fireside chat at Leerink will be made available at ir.kyvernatx.com following the conference.      #Leerink #Jefferies #Biotech